Pathways induced by PD-1 blockade in cancer immunotherapy have been closely linked to the upregulation of CD47 expression, indicating that elevated CD47 levels post PD-1 inhibitor treatment lead to a reduction in CD8 + T cells, ultimately contributing to drug resistance. This evidence concerns the gene CD47 and cancer.